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Abstract: Approximately one in one hundred children is born with congenital heart disease. Most can be managed with 
corrective or palliative surgery but a small group will develop severe heart failure, leaving cardiac transplantation as the 
ultimate treatment option. Unfortunately, due to the inadequate number of available donor organs, only a small number of 
patients can benefit from this therapy, and mortality remains high for pediatric patients awaiting heart transplantation, es-
pecially compared to adults. The purpose of this review is to describe the potential role of mechanical circulatory support 
in this context and to review current experience. For patients with congenital heart disease, ventricular assist devices are 
most commonly used as a bridge to cardiac transplantation, an application which has been shown to have several impor-
tant advantages over medical therapy alone or support with extracorporeal membrane oxygenation, including improved 
survival to transplant, less exposure to blood products with less immune sensitization, and improved organ function. 
While these devices may improve wait list mortality, the chronic shortage of donor organs for children is likely to remain 
a problem into the foreseeable future. Therefore, there is great interest in the development of mechanical ventricular assist 
devices as potential destination therapy for congenital heart disease patients with end-stage heart failure. This review first 
discusses the experience with the currently available ventricular assist devices in children with congenital heart disease, 
and then follows to discuss what devices are under development and may reach the bedside soon.  
Keywords: Mechanical circulatory support, Congenital heart disease, end-stage heart failure, pediatric heart transplantation, 
pediatrics, extracorporeal life support. 
INTRODUCTION 
  Although survival rates for patients with repaired or pal-
liated congenital heart disease are now quite good, there re-
main a minority of patients who may experience either acute 
heart failure in the early postoperative period or end-stage 
heart failure much later [1]. Mechanical circulatory support 
can offer several important applications in the management 
of both acute and chronic heart failure following surgery for 
congenital heart disease [2-4]. Extracorporeal life support 
(ECLS) in the setting of congenital heart disease is most 
commonly applied in the early postoperative period for acute 
heart failure, and these patients are typically supported with 
extracorporeal life support systems, such as extracorporeal 
membrane oxygenation (ECMO). For patients with end-
stage heart failure, the best definitive treatment is heart 
transplantation. For the repaired or palliated congenital heart 
disease patient with severe and intractable ventricular dys-
function, mechanical circulatory support can serve as a 
bridge to transplantation. However, the outcomes of ECLS 
for this indication are not as good as in respiratory failure or 
other emergency indications [5]. Relatively lower survival 
rates have been observed in patients who were younger and 
had cardiac failure, with recent survival rates of 39% for 
neonatal cardiac patients [6].  
*Address correspondence to this author at the Professor of Pediatrics, Sur-
gery, and Bioengineering, Penn State Milton S. Hershey Medical Center, 
Department of Pediatrics, H085, 500 University Drive, P.O. Box 850, Her-
shey, PA 17033-0850; Tel: (717) 531-6706; Fax: (717) 531-0355;  
E-mail: aundar@psu.edu 
  Against this background, ventricular assist devices 
(VADs) have experienced increasing use as a bridge to 
transplantation in children with encouraging results. Unfor-
tunately, the number of potential heart transplant recipients 
far exceeds the donor pool, and heart transplantation cannot 
adequately meet the needs of this patient population [7]. 
Consequently, the development of cardiac assist devices for 
destination therapy represents an attractive future goal, and is 
the subject of ongoing research [8].  
  In adults, VADs have been used as bridge to recovery or 
transplant, and even as destination therapy. In adults with 
end-stage heart failure, VAD support has been associated 
with improved survival versus medical management [9]. Al-
though clinical experience with VAD support of heart failure 
in congenital heart disease is still limited, an increase in 
VAD use in children has occurred since smaller devices be-
came more widely available [10-13].  
  In 2010, Gazit and colleagues provided a comprehensive 
description and analysis of the options for mechanical circu-
latory support in children awaiting heart transplantation [14], 
and summarized their institution’s experience with the Berlin 
Heart as a bridge to transplantation [15]. In this review, we 
seek to provide an update on the most recent studies regard-
ing pediatric mechanical circulatory support for children 
with congenital heart disease and end-stage heart failure, 
with a special focus on the options for long-term support, 
namely VADs and other systems.  Mechanical Circulatory Support for End-Stage Heart  Current Cardiology Reviews, 2011, Vol. 7, No. 2    103 
Congenital Heart Disease: The Scope of the Problem  
  Approximately one in one hundred neonates is born with 
congenital heart disease [16]. It is estimated that 0.4% of 
live-born infants require a heart operation or catheter-based 
intervention. The overall outlook has improved for these pa-
tients, with 85% of children born with congenital heart dis-
ease now surviving into adulthood [17]. During an earlier era 
when the mortality associated with reconstructive surgery 
was higher, the concept of primary heart transplantation for 
infants with complex disease was attractive, potentially of-
fering improved survival compared to corrective surgery 
[18]. However, the availability of pediatric donor hearts 
never reached levels that could meet the needs of the popula-
tion with congenital heart disease. For the last decade, the 
number of pediatric heart transplantations in the United 
States has remained essentially flat at less than 500 cases an-
nually [19]. Meanwhile, surgical results for congenital heart 
disease have improved, and the vast majority of these pa-
tients can now be successfully managed with primary repair 
or staged palliation. 
End-stage Heart Failure in Congenital Heart Disease  
  Despite advances in corrective and palliative surgery for 
congenital heart disease, some patients will develop acute or 
chronic end-stage heart failure and will require cardiac 
transplantation. These patients with congenital heart disease 
and end-stage heart failure fall into three broad categories. 
First, there are some infants without surgical options other 
than cardiac transplantation due to the complexity of their 
problem (e.g., unresectable cardiac tumor). Second, some 
patients reach the point of end-stage heart failure after one or 
more palliative operations which adversely affect outcomes 
[20]. It is estimated that approximately 10% of Fontan pallia-
tions experience early failure. There is some experience with 
heart transplantation after failed Fontan palliation of single-
ventricle heart disease, and successful transplantation is pos-
sible after this type of palliation for single ventricle, albeit 
difficult [21]. Third, some patients with unrepaired congeni-
tal heart disease may survive well into adulthood but eventu-
ally progress to end-stage heart failure. For example, patients 
with congenitally corrected transposition of the great arteries 
(ventricular inversion) may present with failure of their sys-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The Penn State Hershey ECLS circuit.  
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temic ventricle in fourth decade of life [22]. In this situation, 
the first operation for these patients may be cardiac trans-
plantation. There is a recent report of successful palliation of 
three patients with congenitally corrected transposition of the 
great arteries with LVAD [23].  
  Another interesting aspect is that pre-treatment with 
ECLS may help to improve pulmonary hypertension in pa-
tients awaiting cardiac transplantation for congenital heart 
disease although it is unclear whether this improves the 
overall outcome [24-25]. 
  Given the incidence of congenital heart disease, there 
will be a substantial number of patients with congenital heart 
disease in need of alternative treatment modalities. For in-
stance, with approximately 4.3 million births in the United 
States in 2007 [26], it can be expected that more than 40,000 
patients will be affected by congenital heart disease. It is 
thought that there are now close to 1,000,000 Americans 
with congenital heart disease. This value stands in stark con-
trast to the less than 500 pediatric cardiac transplantations 
performed annually [19]. Therefore, there is a vital need for 
alternative therapies for end-stage heart failure in this grow-
ing population. 
PEDIATRIC MECHANICAL CIRCULATORY SUP-
PORT: CURRENT DEVICES 
Berlin Heart EXCOR Pediatric 
  The Berlin Heart EXCOR Pediatric is the most common 
pediatric VAD for bridge to transplant in use today. Over 
800 pediatric patients worldwide have been supported with a 
Berlin Heart as a bridge to cardiac recovery or transplant 
[http://www.berlinheart.de/index.php/newsroom/content/pres
s_us/press_release_us]. While survival to transplantation is 
good (63%-89%) [15, 27-29], complications are also com-
mon in patients supported with the EXCOR device, such as 
thromboembolism (22%), bleeding requiring reoperation 
(29%), infection (67%), and adverse neurological events 
(69%) [15, 27-29]. Of these morbidities, the persistently high 
rate of stroke remains a troubling aspect associated with 
VAD support. 
PEDIATRIC VAD EXPERIENCE IN GERMANY AND 
EUROPE 
  Following the first implantation of the Berlin Heart EX-
COR Pediatric at the German Heart Institute Berlin in 1990, 
this institution has accrued the largest single-center experi-
ence with the device worldwide. In 2006, Hetzer and col-
leagues reported their 15-year experience with the Berlin 
Heart EXCOR Pediatric [30]. In this report, the authors di-
vided their experience into two time periods, and reported a 
number of salient findings. In the later era (i.e., 1999 to 
2005), patients were more likely to be treated with a left 
VAD (LVAD) only, and had a higher survival to hospital 
discharge following either recovery or heart transplantation. 
Survival to discharge improved for both patients with car-
diomyopathy (from 43% to 76%), and those with postcar-
diotomy heart failure (from 0% to 57%). Significant gains in 
outcomes were appreciated for the infants in the study, with 
higher rates of primary sternal closure, extubation, and sur-
vival. The authors attributed these improvements to earlier 
implantation of VADs, and a number of modifications both 
in the VAD circuit and in the management of anticoagula-
tion.  
  In 2010, Fan and colleagues from Berlin provided an up-
date to their earlier experience with a focus on the support of 
young patients with the EXCOR Pediatric [31]. The authors 
reviewed a population of 56 small children with body sur-
face area less than 1.2 m
2 who were treated with VAD sup-
port from 1999 to 2009. Patients with cardiomyopathy ac-
counted for the largest share (73%) of the group, with con-
genital heart disease comprising a lesser fraction (25%). This 
review noted a trend toward improved survival in patients 
treated only with an LVAD versus biventricular assist device 
(BiVAD) support. Consistent with an earlier report from 
Blume et al. [10], significantly decreased survival was seen 
in patients with congenital heart disease. 
  In 2010, Brancaccio and colleagues also reported their 
experience with the Berlin Heart as a bridge to transplanta-
tion in small children [32]. They reviewed 10 children 
weighing less than 10 kg who were supported from 2002 to 
2010, with a median age of 10.4 months and weight of 6.4 
kg. ECLS was used in two patients prior to VAD support. 
An LVAD alone was used in seven patients, with a BiVAD 
in three. Half of the patients required at least one pump ex-
change. Three patients died of stroke, and one of sepsis. Five 
patients (50%) were successfully bridged to transplant, while 
the last was still awaiting transplant. Early post-transplant 
survival in this small cohort was 100% at a median of 7.5 
months. These authors suggested that this type of mechanical 
support can be an effective bridge to transplantation strategy, 
but is currently associated with significant morbidity and 
mortality.  
PEDIATRIC VAD EXPERIENCE IN NORTH AMER-
ICA 
  Although the Berlin Heart EXCOR came into routine 
clinical use in 1992 at the German Heart Institute Berlin 
[30], the device was not available in the United States until a 
decade later. Although the first implantation of the EXCOR 
in the United States occurred in 2000, widespread use was 
not seen until 2004 [11]. Prior to this time, VAD use in chil-
dren in North America was primarily limited to older, larger 
patients who could be supported with the smallest adult-size 
VADs, such as the Thoratec VAD. Consequently, support 
options for infants and small children were usually limited to 
ECLS or centrifugal assist systems.  
  In 2006, Blume and colleagues [10] reported on the 
growing use of VADs in children as a bridge to heart trans-
plantation. During a ten-year time frame ending in 2003, 
ventricular assist devices were implanted in 99 (4%) of 2375 
children listed for heart transplantation. Over the course of 
the study, there was a three-fold increase in the use of 
VADs, with devices present at transplant in 2.3% of patients 
in the early cohort but in 7.2% of patients in the late cohort. 
In this study, patients supported with VADs were more 
likely older (median 13.3 versus 4.8 years), larger (median 
56 versus 20 kg), and less likely to have congenital heart dis-
ease (22% versus 60%) than non-VAD patients. Two short-
term devices were used: the Bio-Pump (Medtronic, Minnea-
polis, MN) in 16, and the BVS 5000 (Abiomed Inc., Mechanical Circulatory Support for End-Stage Heart  Current Cardiology Reviews, 2011, Vol. 7, No. 2    105 
Danvers, MA) in 10. Four long-term devices were used: the 
Thoratec VAD in 53 patients, a Heartmate LVAS (Thoratec 
Corp., Pleasanton, CA) in 13, a Novacor LVAS (WorldHeart 
Inc., Oakland, CA) in 3, and the Berlin Heart EXCOR Pedi-
atric in 1. The major diagnostic group was comprised of pa-
tients with cardiomyopathy (78%), with congenital heart dis-
ease accounting for the remainder (22%). Risk factors for 
death while awaiting a transplant included earlier era of im-
plantation, female gender, and diagnosis of congenital heart 
disease.  
  In 2008, Davies and others provided a follow-up to the 
work of Blume et al. by examining the effect of type of me-
chanical circulatory support on post-transplantation survival 
[33]. Using data from the United Network for Organ Shar-
ing, these authors studied 2532 transplantations in children 
less than 19 years of age from 1995 to 2005. Mechanical cir-
culatory support was present at the time of transplantation in 
431 patients (17%), and included VADs in 241 (9.5%), 
ECLS in 171 (6.8%), and intra-aortic balloon pumps in 19 
(0.8%). Dilated cardiomyopathy accounted for the majority 
of patients receiving mechanical support, with congenital 
heart disease accounting for a minority (29%). When me-
chanical support was implemented, patients with cardiomy-
opathy were more often supported with VADs (n=180) than 
ECLS (n=66). On the contrary, patients with congenital heart 
disease were more commonly supported with ECLS (n=90) 
and less so with VADs (n=33). Compared to the VAD pa-
tients, ECLS patients were both younger (3.8 versus 12.2 
years) and smaller (16.8 versus 52.9 kg). These authors 
showed that 5- and 10-year post-transplantation survival was 
better for patients supported with VADs than for those sup-
ported with ECLS, and that late survival was similar between 
patients receiving VADs and those who did not require me-
chanical support. Although ECLS was associated with de-
creased long-term survival, this effect was primarily exhib-
ited in the early postoperative period. ECLS patients had 
higher rates of end-organ failure, and consequently had a 
higher early mortality rate. Beyond this initial postoperative 
period, the survival curves for all the patient groups were 
parallel. The association of ECLS with higher early mortality 
was independent of the diagnosis (e.g., cardiomyopathy ver-
sus congenital heart disease). This study made no distinction 
regarding the type of VAD, and did not report on any spe-
cific devices. The authors proposed that some of the smallest 
patients who were classified in the VAD cohort were likely 
supported with centrifugal assist devices and not with pneu-
matic pulsatile assist devices. These small patients with a 
body surface area less than 0.3 m
2 were found to have a 
higher long-term mortality. The authors suggested that these 
patients, if they had in fact been supported with centrifugal 
devices, may not have received some of the benefits seen 
with the pulsatile VADs, such as higher rates of extubation 
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and mobilization, and that these factors may have contrib-
uted to the poorer outcomes in these patients. 
  In 2009, Imamura and colleagues from Arkansas reported 
their experience with mechanical circulatory support as a 
bridge to transplantation [34]. They reviewed patients from 
2001 to 2008 who received mechanical support as a bridge to 
transplant. The patient cohorts were evenly distributed be-
tween ECMO (n=21) and Berlin Heart EXCOR (n=21). The 
overall incidence of congenital heart disease was lower 
(24%) than the incidence of either cardiomyopathy (50%) or 
myocarditis (26%). Although there was a trend toward 
younger age in the ECMO group compared to the VAD 
group (2.1 versus 4.1 years, p=0.07), the groups were found 
to be otherwise similar in weight, etiology of heart failure, 
and degree of co-morbidity. Despite mortality in the first 5 
consecutive patients supported with VADs, a survival advan-
tage was demonstrated for VAD support compared to 
ECMO. Survival to transplant, recovery, or continued sup-
port was 57% in the ECMO group and 86% in the EXCOR 
group. These authors suggested that the presence of the 
learning curve in this series may actually lead to an underes-
timation of the survival benefit of VAD support. EXCOR 
use was also associated with significantly longer periods of 
support versus ECMO (mean 42 versus 15 days). Unfortu-
nately, both modalities were associated with significant neu-
rologic morbidity, with equivalent stroke rates of 38%. One 
important decision associated with the implementation of 
VAD support is the choice of device implantation in one or 
both ventricles. These authors treated all patients who were 
transitioned from ECLS with biventricular devices. All re-
maining patients (who had not been on ECLS) received an 
LVAD alone, and no patient later required the addition of a 
right VAD. These authors suggested that ECMO and VADs 
should not be viewed as competing technologies, but rather 
as complementary therapies. Pointing to utility of ECMO, 
the authors cited the typically wider availability and greater 
experience with ECLS, especially for emergency support and 
for use in small infants. For example, in this study, one third 
of patients included in the VAD cohort had been initially 
supported with ECMO, thus making ECMO a bridge to 
VAD. In 2010, Stein and colleagues from Stanford updated 
their experience with pediatric VAD support as a bridge to 
transplantation, offering the largest United States single-
center report to date [12]. Using data drawn from the Inter-
agency Registry for Mechanically Assisted Circulatory Sup-
port, they reported on outcomes for 25 children less than 18 
years old who were supported with VADs from 1998 to 
2007. Patients with congenital heart disease comprised a 
small fraction of the population (16%), with various forms of 
cardiomyopathy accounting for the remainder. ECMO sup-
port preceded VAD implantation in 5 (19%) of patients. The 
most commonly used devices were the Thoratec pediatric 
VAD in 16 (59%) and the Berlin Heart EXCOR in 9 (33%), 
consistent with a slightly older and larger patient population 
with median age of 12 years and weight of 47 kg. While 
overall survival to transplantation was encouraging at 74%, 
considerable morbidity was appreciated, with over half of 
the patients having the events of respiratory failure, major 
infection, major bleeding, hepatic dysfunction, and right 
heart failure. Additionally, neurologic morbidity was high-
lighted by a major stroke rate of 48% and a dysfunction rate 
of 59%. Neurologic events were the most common cause of 
mortality, accounting for 3 of the 7 deaths in the study. Go-
ing forward, the larger unanswered question, according to 
the authors, remains when to initiate VAD support in chil-
dren. As suggested by others [30], earlier initiation of VAD 
therapy may improve survival, as patients receive support 
prior to the onset of vital organ dysfunction or failure. On the 
other hand, premature use of VAD therapy may unnecessar-
ily expose some children to the risks and morbidities that ac-
company this type of support, as some patients may have 
survived to transplantation without device implantation. Ac-
cording to the authors, this question of timing of VAD sup-
port presents an ongoing important and challenging clinical 
scenario. 
  In 2010, Humpl and colleagues from Toronto reported 
their experience with Berlin Heart [27]. From 2004 to 2008, 
15 patients with an average age of 8.8 years and weight of 
31.1 kg were supported with the device. Dilated cardiomy-
opathy was the predominant diagnosis (n=14, 93%), with 
congenital heart disease in one patient with a single ventricle 
Glenn circulation. ECMO was used initially in 3 patients 
(20%) prior to VAD support. All patients were supported 
with biventricular devices, with the exception of the single 
ventricle patient who received a single VAD. Adverse neu-
rologic events were seen in 3 patients (20%). No patients 
were weaned to recovery, and two patients (13%) died on 
while on VAD support. Survival to transplant was seen in 13 
patients (87%), including the patient with congenital heart 
disease.  
  In 2011, Morales et al. reported on the initial North 
American experience with the Berlin Heart EXCOR Pediat-
ric [11]. Prior to the start of the Berlin Heart investigational 
device exemption trial in 2007, nearly 100 devices were im-
planted at centers in the United States and Canada. These 
authors attempted to aggregate this early experience, and 
provide an overview of its efficacy as a bridge to transplant. 
Data was available for 73 of 97 patients covering a period 
from 2000 to 2007. As in other reports, congenital heart dis-
ease was seen in a minority of patients (26%), while dilated 
cardiomyopathy was the most common cause of heart failure 
(58%). As a cohort, these patients were small, reflecting the 
niche of the Berlin Heart, with a median patient age of 2.1 
years and weight of 11 kg. ECMO provided a bridge to VAD 
support in 22 patients (30%). A majority of patients were 
treated with the LVAD alone (n=42, 57%), while BiVADs 
were used in the remainder. Younger age and biventricular 
support were risk factors for mortality while awaiting trans-
plantation. Survival to transplantation was seen in 51 pa-
tients (70%) and survival to recovery in 5 (7%). Contrary to 
other reports [10, 31], congenital heart disease was not found 
to be a risk factor for death on mechanical support. Addi-
tionally, the use of ECMO prior to VAD implantation was 
also not associated with increased mortality. Although this 
report represents the largest single-device experience for pe-
diatric VAD support in North America, the authors acknowl-
edge that limited conclusions can be drawn from this incom-
plete clinical data. For example, no morbidity data was 
available, precluding any comment about the rates of brain 
injury, thromboembolic complication, infection, or device 
failure. With this type of morbidity data being gathered in 
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and efficacy will be forthcoming. In the meantime, these 
authors concluded that the Berlin Heart VAD is likely a fea-
sible therapy as a bridge to transplantation.  
PEDIATRIC VAD SUPPORT OF THE SINGLE VEN-
TRICLE PATIENT 
  Some authors have reported that they do not offer VADs 
to patients with single ventricle congenital heart disease [34], 
instead opting to support those children with ECLS. Never-
theless, there are a handful of case reports from the last dec-
ade that describe the use of VAD support for single ventricle 
heart failure. VanderPluym and others provided such a case 
report as well as a review of the literature regarding the use 
of ventricular assist devices in pediatric patients with univen-
tricular hearts [35]. These authors described VAD support of 
a 3-year-old with early heart failure following a Fontan op-
eration. The patient’s anatomy was revised back to a bidirec-
tional cavopulmonary Glenn connection, with initiation of 
ECMO. Support was later converted to a Berlin Heart EX-
COR Pediatric device which was implanted with systemic 
right ventricular and aortic cannulation. Following nearly six 
months of VAD support, this patient underwent successful 
hear transplantation. As these authors acknowledge, the pau-
city of published reports on VAD support in single ventricle 
patients precludes firm recommendations regarding surgical 
management strategy. With this caveat, the authors proposed 
the following techniques for VAD support of palliated 
univentricular hearts. For patients with shunt dependent cir-
culation (e.g., a Norwood patient with a Blalock-Taussig 
shunt), adequate support should be feasible with systemic 
ventricular inflow and aortic outflow. However, due to the 
parallel circulations and pulmonary runoff, higher pump 
flow rates will likely be required. Similarly, patients with a 
bidirectional cavopulmonary connection (e.g., a Glenn or 
Hemi-Fontan patient), may be adequately supported with the 
same cannulation strategy employing systemic ventricular 
inflow and aortic outflow. Finally, VAD support of the fail-
ing Fontan can be managed in several ways, depending on 
the anatomy and physiology of the specific patient. In the 
case of pump failure due to ventricular dysfunction, VAD 
support with systemic ventricular inflow and aortic outflow 
may be sufficient. However, if elevated pulmonary vascular 
resistance leads to systemic venous hypertension and right-
sided failure, then a second VAD may be required to support 
flow through the pulmonary circulation. In this situation, 
separation of the two circulations is performed by takedown 
of the Fontan pathway.  
PEDIATRIC MECHANICAL CIRCULATORY SUP-
PORT: DEVICES UNDER TESTING OR DEVELOP-
MENT 
Maquet Cardiohelp 
  The Maquet Cardiohelp is a compact, portable extracor-
poreal life support system. It has been used with the Maquet 
Quadrox-i adult oxygenator to provide emergency life sup-
port due to cardiogenic shock during patient transport. All 
components of this circuit are integrated, but changing the 
oxygenator to a neonatal or pediatric version (e.g., Maquet 
Quadrox-i neonatal or Quadrox-i pediatric) could expand the 
usage of this device to pediatric patients. The adult circuit 
has a maximum flow rate of 7 L/min, which limits the upper 
bound on flow rates in potential pediatric patients to the 
maximum of the chosen oxygenator. However, this system is 
currently designed only for short-term use, and would re-
quire investigations into mechanical issues associated with 
longer use in order to make the transition to pediatric appli-
cations [http://www.maquet-cardiohelp.com/cardiohelp-
system/introduction.html]. 
CircuLite Synergy System 
  Originally intended for partial support in adult patients, 
the CircuLite Synergy System (CircuLite, Inc., Saddle 
Brook, NJ) is an implantable micro-pump with a maximum 
capability of 3 L/min. Due to its small size and compatible 
flow rates, CircuLite was awarded a National Institutes of 
Health Fast-Track Phase I-II Small Business Innovation Re-
search grant in July 2009 to convert their adult micro-pump 
into a pediatric specific pump capable of complete unloading 
of the heart. In preliminary juvenile bovine studies, the Cir-
cuLite Synergy System provided adequate left ventricular 
unloading, normal end-organ function, and no device mal-
functions at a two-week time point post-implantation [36]. 
Medos Deltastream DP3 
  An improvement to the previous Medos Delastream DP2 
(MEDOS Medizintechnik AG, Stolberg, Germany), this new 
diagonal flow rotary pump is approved in Europe for up to 7 
days of continuous use. In addition to the ability to generate 
both pulsatile and non-pulsatile flow, the DP3 pump also has 
a low priming volume (16 mL) and very fine control over 
low flow rate adjustments, making it suitable for neonatal 
use [37]. Preclinical studies in adult sheep demonstrated the 
ability of the DP3 pump to run for 7 days without incident in 
5 out of 6 animals [38]. Initial clinical results show low 
thrombogenicity and hemolysis associated with the pump 
[37]. 
Ventracor Ventrassist 
  Currently undergoing clinical trials, the Ventrassist pump 
(Ventracor, Inc., Sydney, Australia) is a third generation, 
implantable LVAD with a range of 1.5-10 L/min. Currently, 
it is being investigated for bridge to transplant in adult pa-
tients. In 98 adult patients, 85% and 82% of patients were 
alive on support or transplanted at 6 and 12 months post-
implantation [http://www.ventracor.com]. Due to its larger 
size, this device is not currently feasible for use in neonates, 
but larger pediatric patients may benefit from the future ap-
plication of this device. 
Abiomed Impella 5.0 
  The Abiomed Impella 5.0 (ABIOMED, Inc., Danvers, 
MA) is a minimally invasive catheter pump that can generate 
flows of 5 L/min for up to 7 days. It is currently approved by 
the United States Food and Drug Administration (FDA) as 
an investigational device and is available in Europe under 
CE Mark approval. In Europe, it has been used in more than 
250 adult patients, providing support for post-cardiotomy 
cardiogenic shock or as a bridge to transplant. The low tech-
nical requirements of this device make it ideal for use in 108    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Clark et al. 
high-risk patients and those with multi-organ dysfunction, 
which would make para-corporeal implantable LVADs un-
suitable. Several reports of adult patients in refractory car-
diogenic shock have shown that use of the Impella 5.0 
helped restore ventricular and end-organ function, and con-
tributed to successful bridging of those patients to longer-
term mechanical circulatory support devices [39]. 
  The previous model Impella 2.5 was evaluated in small 
lambs to assess the feasibility of the catheter pump design 
for use in pediatric patients. Five out of the six lambs sur-
vived to two-weeks and the authors concluded that the im-
planted system generated stable flow at pediatric flow rates 
for 14 days, while maintaining hematologic stability with 
minimal tissue injury due to the implantation procedure [40]. 
In 2009, one pediatric patient with refractory cardiogenic 
shock due to viral myocarditis was stabilized with this de-
vice and successfully bridged to recovery [41]. 
THE PUMPS FOR KIDS, INFANTS, AND NEONATES 
(PUMPKIN) PROJECT 
  The National Heart, Lung, and Blood Institute (NHLBI) 
recently awarded four grants for the development of new pe-
diatric life support pumps, under the PumpKIN program. 
The goal of this program is to develop small, implantable 
pumps for use in small pediatric and neonatal patients. The 
current grant awardees include: LaunchPoint Technologies, 
Inc, Pittsburgh, PA and consortium; Ension, Inc., Pittsburgh, 
PA; University of Maryland School of Medicine; and Jarvik 
Heart, Inc., New York, NY. 
  LaunchPoint Technologies and its collaborators at the 
University of Pittsburgh are designing the PediaFlow Pediat-
ric VAD. Their newest version, the PF3, is attempting to 
meet the design requirements of full implantability in chil-
dren 3-15 kg, flow rates of 0.3-1.5 L/min, and be sustainabil-
ity of 6 months of circulatory support, while minimizing 
hemolytic trauma, thrombosis, and infection 
[www.launchpnt.com]. 
  Jarvik Heart, in collaboration with the University of 
Maryland and others, is redesigning the Jarvik 2000 axial 
flow pump for pediatric use. In juvenile sheep experiments, 
it was shown that the pediatric Jarvik 2000 could pump 1.4-
2.5 L/min of blood for up to 70 days without important 
hemolysis or end-organ damage [42]. The infant Jarvik 2000 
model is still under development. 
  Both the Ension pCAS system and Pedi PumpLung from 
the University of Maryland will be self-contained devices 
capable of pumping and oxygenating blood simultaneously 
[43]. It remains to be seen whether either device will be pro-
vide comparable capability to the Maquet CardioHelp cur-
rently in use. 
Penn State Hershey Pediatric ECLS System 
  Perfusion quality is of the utmost importance to neonatal 
and pediatric patients undergoing ECLS. The minimization 
of post-ECLS complications, including neurological and 
other vital organ injury, depend on adequate perfusion of vi-
tal tissues. To this end, the faculty, perfusionists, and nurses 
at the Penn State Hershey Pediatric Cardiovascular Research 
Center have designed a new neonatal and pediatric ECLS 
circuit, whose components have been selected based on rig-
orous studies conducted by our center [44-50]. This new cir-
cuit has many advantages over previous systems, including: 
reduced priming time and volume, smaller size, significantly 
reduced pressure drop (~90% lower) through the oxygenator, 
and the ability to be staffed by a nurse instead of a dedicated 
respiratory therapist. We have already trained 110 clinicians 
from five institutions in 2010, as well as our own in-house 
staff.  
CONCLUSIONS 
  Patients with congenital heart disease and end-stage heart 
failure currently have a limited number of options for long-
term mechanical circulatory support. In recent years, signifi-
cant advances have been made, and more devices are under 
development with some having already reached pre-clinical 
trials. Over the next few years, continued improvements in 
the field of pediatric mechanical circulatory support are ex-
pected, including the addition of new pediatric VADs, new 
magnetically levitated centrifugal pumps, and new low pres-
sure drop hollow-fiber membrane oxygenators for ECLS.  
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